Skip to main content

Table 1 Description of included randomized controlled trials

From: Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review

Study Study design Grade Treatment options Study location dosage of drugs Treatment
      LAM LdT  
Lai 2005[6] RCT, DB 5 LAM vs LdT Global 100 mg 400/600 mg 12 months
Lai 2007[7] RCT, DB 5 LAM vs LdT Global 100 mg 600 mg 12 months
Rasenack 2007[17] RCT, DB 4 LAM vs LdT Global 100 mg 600 mg 24 months
Jia 2007[16] RCT, DB 4 LAM vs LdT China 100 mg 600 mg 24 months
Hou 2008[10] RCT, DB 4 LAM vs LdT China 100 mg 600 mg 12 months
Liaw 2009[15] RCT, DB 5 LAM vs LdT Global 100 mg 600 mg 24 months
Cai 2009[13] RCT, DB 5 LAM vs LdT China 100 mg 600 mg 12 months
Yang 2009[14] RCT 3 LAM vs LdT China 100 mg 600 mg 12 months
Zhong 2009[11] RCT 3 LAM vs LdT China 100 mg 600 mg 12 months
Chen 2009[9] N/A 2 LAM vs LdT China 100 mg 600 mg 12 months
Tang 2009[8] RCT 3 LAM vs LdT China 100 mg 600 mg 12 months
  1. RCT, randomized controlled trial; DB, double blind; LAM, Lamivudine; LdT, Telbivudine
Back to article page

Virology Journal

ISSN: 1743-422X